Back to top
more

AMN Healthcare Services (AMN)

(Delayed Data from NYSE)

$18.72 USD

18.72
1,681,403

-0.54 (-2.80%)

Updated Sep 19, 2025 04:00 PM ET

After-Market: $18.72 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth F Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 245)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain CONMED (CNMD) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about CONMED (CNMD) owing to its broad product spectrum.

Zacks Equity Research

AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

AMN Healthcare Services (AMN) closed at $103 in the latest trading session, marking a +0.2% move from the prior day.

Zacks Equity Research

AMN Healthcare Services (AMN) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, AMN Healthcare Services (AMN) closed at $103.46, marking a +0.46% move from the previous day.

Zacks Equity Research

AMN Healthcare (AMN) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

AMN Healthcare (AMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Equity Research

AmerisourceBergen (ABC) to Repurchase Common Stock Worth $200M

by Zacks Equity Research

AmerisourceBergen (ABC) announces a share repurchase worth $200 million in concurrence with the sale of its shares by one of its shareholders, Walgreens Boots Alliance, under Rule 144.

Zacks Equity Research

LabCorp (LH) Gains on Innovation Amid Currency Headwinds

by Zacks Equity Research

LabCorp (LH) enters into a collaboration with Becton, Dickinson and Company to help match patients with critical and potentially life-changing treatments for cancer and other diseases.

Zacks Equity Research

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH), led by strength in its Drug Development business.

Zacks Equity Research

HealthEquity (HQY) Stock Falls 1.6% Despite Q3 Earnings Beat

by Zacks Equity Research

HealthEquity (HQY) witnesses solid growth in HSAs besides recording robust performances in all its segments in the third quarter of fiscal 2023.

Zacks Equity Research

Quest Diagnostics' (DGX) New Deal to Extend Laboratory Access

by Zacks Equity Research

Quest Diagnostics' (DGX) new collaboration with Northern Light Health will enhance access to diagnostics services in Maine.

Zacks Equity Research

Cooper Companies (COO) Q4 Earnings Miss Estimates, Revenues Up

by Zacks Equity Research

Despite a decline in the bottom line, Cooper Companies' (COO) fiscal fourth-quarter revenues reflect a solid segmental performance.

Zacks Equity Research

LabCorp's (LH) New APH Lab to Expand Global Capabilities

by Zacks Equity Research

LabCorp's (LH) new laboratory is likely to advance clinical trials across therapeutic areas like oncology, hemato-oncology and liver diseases.

Zacks Equity Research

Masimo (MASI) W1 Watch With Hi to Improve Patient Outcome

by Zacks Equity Research

Masimo's (MASI) full-market release of the Hi for the Masimo W1 watch is likely to significantly improve RPM.

Zacks Equity Research

3 Reasons to Hold QuidelOrtho (QDEL) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about QuidelOrtho (QDEL) owing to its strong product portfolio.

Zacks Equity Research

Zimmer Biomet (ZBH) Procedure Volume Gain Aids Amid FX Hurdles

by Zacks Equity Research

Zimmer Biomet (ZBH) continues to face significant challenges in terms of unfavorable foreign exchange, supply, inflation and staffing shortage.

Zacks Equity Research

3 Reasons to Retain Avanos (AVNS) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Avanos (AVNS) owing to its strong product line and focus on R&D.

Zacks Equity Research

Acadia (ACHC) Reveals its Long-Term Goals: What You Should Know

by Zacks Equity Research

From 2022 to 2028, Acadia Healthcare (ACHC) expects to see a 9-11% CAGR in revenues.

Zacks Equity Research

3 Reasons to Retain Allscripts (MDRX) Stock in Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Allscripts (MDRX) owing to its strategic alliances.

Zacks Equity Research

The Joint (JYNT) Expands Operations to Alaska With 3 Clinics

by Zacks Equity Research

The Joint's (JYNT) expansionary move is expected to be a prudent one, given the growing demand for affordable and convenient chiropractic care in the region.

Zacks Equity Research

Quest Diagnostics (DGX) Volume Growth Aids, Margin Woes Stay

by Zacks Equity Research

Quest Diagnostics' (DGX) legacy base business is growing amid softer utilization trends.

Zacks Equity Research

Centene (CNC) Concludes Magellan Rx Divestment to Prime

by Zacks Equity Research

Centene (CNC) completes Magellan Rx divestment within the scheduled time.

Zacks Equity Research

Here's Why You Should Retain Hologic (HOLX) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Hologic (HOLX) on the back of its continued strength in the Breast Health arm.

Zacks Equity Research

Catalent (CTLT) Expands Facility Capabilities in Shanghai

by Zacks Equity Research

Catalent's (CTLT) latest capability expansion is expected to boost its business in the clinical trials space in its Asia-Pacific Clinical Supply Services network.

Zacks Equity Research

Masimo (MASI) Announces Positive Study Results on PBM by SpHb

by Zacks Equity Research

Masimo's (MASI) SpHb is likely to enhance transfusion management and post-operative patient outcomes on patients.

Zacks Equity Research

Merit Medical (MMSI) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Merit Medical's (MMSI) slew of product launches.

Zacks Equity Research

Thermo Fisher (TMO) End Markets Grow Strong, Margin Woe Stays

by Zacks Equity Research

Thermo Fisher (TMO) witnesses strength in three of its four end markets, categorized either by customer type or geography.